BackgroundCheck.run
Search For

Thomas J Lanza, ~661924 Seaman Ct, Toms River, NJ 08753

Thomas Lanza Phones & Addresses

1924 Seaman Ct, Toms River, NJ 08753    732-5067774   

422 Eisenhower Ave, Seaside Heights, NJ 08751    732-8306612   

54 Todd Cir, North Brunswick, NJ 08902    732-8210005   

Kenilworth, NJ   

Monmouth Junction, NJ   

Bordentown, NJ   

Work

Company: Lanza & Lanza, LLP Address: 5 Main St Po Box 2520, Flemington, NJ 08822 Specialities: Power Of Attorney - 34% • General Practice - 33% • Real Estate - 33%

Education

Degree: JD School / High School: Seton Hall University School of Law

Ranks

Licence: New Jersey - Active Date: 1988

Mentions for Thomas J Lanza

Professional Records

Lawyers & Attorneys

Thomas Lanza Photo 1

Thomas J Lanza, Flemington NJ - Lawyer

Address:
Lanza & Lanza, LLP
5 Main St Po Box 2520, Flemington, NJ 08822
908-7536010 (Office), 908-7535535 (Fax)
Lanza &Amp; Lanza 5 Main Street, Flemington, NJ 08822
908-7822600 (Office)
Licenses:
New Jersey - Active 1988
Pennsylvania - Inactive 1988
Education:
Seton Hall University School of LawDegree JD - Law
Specialties:
Power Of Attorney - 34%
General Practice - 33%
Real Estate - 33%
Thomas Lanza Photo 2

Thomas J. Lanza, Flemington NJ - Lawyer

Office:
5 Main St., Flemington, NJ
ISLN:
905630449
Admitted:
1988
University:
Seton Hall University, B.A.
Law School:
Seton Hall University, J.D.

Resumes

Resumes

Thomas Lanza Photo 3

Thomas Lanza

Location:
United States

Business Records

Name / TitleCompany / ClassificationPhones & Addresses
Thomas Lanza
Owner
Tommy's Pallet Yard LLC 1924 Seaman Ct, Toms River, NJ 08753

Publications

Us Patents

Substituted Amides

US Patent:
2004005, Mar 25, 2004
Filed:
Mar 12, 2003
Appl. No.:
10/387265
Inventors:
William Hagmann - Westfield NJ,
Linus Lin - Westfield NJ,
Shrenik Shah - Metuchen NJ,
Ravindra Guthikonda - Edison NJ,
Hongbo Qi - Edison NJ,
Linda Chang - Wayne NJ,
Ping Liu - Edison NJ,
Helen Armstrong - Westfield NJ,
James Jewell - Jersey City NJ,
Thomas Lanza - Edison NJ,
International Classification:
A01N047/28
A01N043/40
A01N043/50
A01N043/56
C07D213/78
C07D233/80
C07D231/36
US Classification:
504/254000, 504/260000, 504/280000, 504/279000, 504/330000, 504/336000, 546/298000, 548/318100, 548/367100, 564/048000, 564/170000
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted Amides

US Patent:
2005023, Oct 20, 2005
Filed:
Apr 19, 2005
Appl. No.:
11/109076
Inventors:
William Hagmann - Westfield NJ,
Linus Lin - Westfield NJ,
Shrenik Shah - Metuchen NJ,
Ravindra Guthikonda - Edison NJ,
Hongbo Qi - Edison NJ,
Linda Chang - Wayne NJ,
Ping Liu - Edison NJ,
Helen Armstrong - Westfield NJ,
James Jewell - Jersey City NJ,
Thomas Lanza - Edison NJ,
International Classification:
A61K031/502
A61K031/428
A61K031/423
A61K031/4196
A61K031/405
A61K031/401
A61K031/165
US Classification:
514248000, 514367000, 514375000, 514423000, 514419000, 514617000, 514383000, 544237000, 548152000, 548217000, 548495000, 548537000
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted Amides

US Patent:
2008017, Jul 17, 2008
Filed:
Feb 1, 2008
Appl. No.:
12/012463
Inventors:
William K. Hagmann - Westfield NJ,
Linus S. Lin - Westfield NJ,
Shrenik K. Shah - Metuchen NJ,
Ravindra N. Guthikonda - Edison NJ,
Hongbo Qi - Edison NJ,
Linda L. Chang - Wayne NJ,
Ping Liu - Edison NJ,
Helen M. Armstrong - Westfield NJ,
James P. Jewell - Jersey City NJ,
Thomas J. Lanza - Edison NJ,
International Classification:
A61K 38/22
A61K 31/44
A61K 31/444
A61K 31/4439
A61K 31/365
A61P 3/04
A61K 31/485
A61K 31/357
A61K 31/155
US Classification:
514 2, 514351, 514335, 514339, 514455, 514635, 514282, 514449
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Anti-Inflammatory Oxazolo [5,4-B]Pyridines

US Patent:
4131677, Dec 26, 1978
Filed:
Apr 27, 1977
Appl. No.:
5/791634
Inventors:
Tsung-Ying Shen - Westfield NJ
Robert L. Clark - Woodbridge NJ
Arsenio A. Pessolano - Colonia NJ
Bruce E. Witzel - Westfield NJ
Thomas J. Lanza - Edison NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3144
C07D49102
US Classification:
424256
Abstract:
The various isomers of oxazolo- and thiazolopyridines having utility as antiinflammatory, antipyretic and analgesic agents are prepared by condensation of an appropriate amino-hydroxypyridine or amino-mercaptopyridine with a carboxylic acid, halide or anhydride.

16-Substituted-4-Aza-3-Oxo-Androstane As 5-Alpha-Reductase Isozyme 1 Inhibitors

US Patent:
5739137, Apr 14, 1998
Filed:
Feb 28, 1996
Appl. No.:
8/601042
Inventors:
Philippe L. Durette - New Providence NJ
William K. Hagmann - Westfield NJ
Thomas J. Lanza - Edison NJ
Soumya P. Sahoo - Old Bridge NJ
Gary H. Rasmusson - Watchung NJ
Richard L. Tolman - Warren NJ
Derek Von Langen - Fanwood NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3158
US Classification:
514256
Abstract:
Compounds of formula (I) are inhibitors of the 5. alpha. -reductase 1 isozyme, and are useful alone, or in combination with a 5. alpha. -reductase 2 inhibitor, for the treatment of androgenic sensitive disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, and benign prostatic hyperplasia. ##STR1##.

5-Methylthio-3-Hydroxybenzo [B]Thiophene-2-Carboxamide Derivatives As Cyclooxygenase And Lipoxygenase Inhibitors

US Patent:
4800211, Jan 24, 1989
Filed:
Aug 18, 1986
Appl. No.:
6/897576
Inventors:
Allan N. Tischler - Westfield NJ
Philippe L. Durette - New Providence NJ
Bruce E. Witzel - Westfield NJ
Thomas J. Lanza - Edison NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3138
C07D33370
US Classification:
514443
Abstract:
3-Hydroxybenzo[b]thiophene-2-carboxamide derivatives have been prepared by: (1) treating a substituted 2-halobenzoate with a thioacetamide. (2) treating a substituted thiosalicylate with an appropriately substituted haloacetamide; and (3) further synthetic modification of compounds prepared above. These compounds have been found to be effective inhibitors of both cyclooxygenase and lipoxygenase and thereby useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandins and/or leukotriene mediated diseases.

Substituted Azetidiones As Anti-Inflammatory And Antidegenerative Agents

US Patent:
5747485, May 5, 1998
Filed:
Jun 5, 1997
Appl. No.:
8/848076
Inventors:
James Doherty - Montvale NJ
Conrad Dorn - Plainfield NJ
Philippe Durette - New Providence NJ
Paul Finke - Milltown NJ
Malcolm Maccoss - Freehold NJ
Sander Mills - Woodbridge NJ
Shrenik Shah - Metuchen NJ
Soumya Sahoo - Old Bridge NJ
William Hagmann - Westfield NJ
Jeffrey Hale - Westfield NJ
Thomas Lanza - Edison NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31395
US Classification:
514210
Abstract:
Substituted azetidinones are herein disclosed for use in the treatment of various elastase-mediated diseases.

3-Hydroxybenzo[B]Thiophene-2-Sulfide Derivatives Compositions, And Method Of Use Therefor

US Patent:
4621091, Nov 4, 1986
Filed:
Oct 9, 1984
Appl. No.:
6/658859
Inventors:
Allan N. Tischler - Westfield NJ
Thomas J. Lanza - Edison NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3134
A61K 3138
C07D33364
C07D40112
US Classification:
514337
Abstract:
3-hydroxybenzo[b]thiophene-2-sulfide derivatives have been prepared by ring closure of an appropriately substituted 2--R. sup. 1 SCH. sub. 2 S-- benzoic acid ester in the presence of a strong base. These compounds have been found to be specific inhibitors of 5-lipoxygenase and thereby useful in the treatment of inflammation, pain and fever associated with inflammation, arthritic conditions, asthma, allergic disorders such as allergic rhinitis and chronic bronchitis, skin diseases like psoriasis and atopic exzema, cardiovascular or vascular disorders, and other leukotriene mediated diseases. Furthermore, these compounds have been found to exhibit cytoprotective activity which does not involve the inhibition of gastric acid secretion but can be used at relatively low dosages for increasing the resistance of gastro-intestinal mucosa to strong irritants.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.